{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:48:17Z","timestamp":1789541297128,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jhep.2025.12.018","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:11:42Z","timestamp":1768824702000},"page":"677-678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tobevibart and elebsiran for the treatment of chronic hepatitis delta"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-2640","authenticated-orcid":false,"given":"Lisa","family":"Sandmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.12.018_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.12.018_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.12.018_bib3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2024.12.033","article-title":"Antiviral treatment of chronic hepatitis D virus infection: to combine or not to combine?","volume":"82","author":"Sandmann","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.12.018_bib4","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(25)00313-7","article-title":"LBO-004 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up","volume":"82","author":"Wedemeyer","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.12.018_bib5","unstructured":"Finite treatment of hepatitis delta with bulevirtide: identification of biomarkers associated with sustained control of HDV infection (BUL-STOP) [Available from: https:\/\/clinicaltrials.gov;NCT06603311]."},{"key":"10.1016\/j.jhep.2025.12.018_bib6","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.12.018_bib7","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.12.018_bib8","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0168-8278(25)00308-3","article-title":"GS-010 Outcomes of 48 weeks of therapy and subsequent 24-week post-treatment period with tobevibart (VIR-3434) and elebsiran (VIR-2218) with or without pegylated interferon alfa-2a in chronic hepatitis B virus infection. Findings from the MARCH study","volume":"82","author":"Gane","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.12.018_bib9","article-title":"A phase 2 trial of tobevibart plus elebsiran in hepatitis D","author":"Asselah","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2025.12.018_bib10","article-title":"Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells","author":"Vincenzetti","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.12.018_bib11","article-title":"Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyond","author":"Sonneveld","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.12.018_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/gutjnl-2024-333026","article-title":"Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989","volume":"74","author":"Mak","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2025.12.018_bib13","article-title":"Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D","volume":"8","author":"Sandmann","year":"2026","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.12.018_bib14","article-title":"Ten-year follow-up after 96 Weeks treatment with peginterferon plus tenofovir in hepatitis D (HIDIT-II): improved clinical outcome after combination therapy","author":"Yurdaydin","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2025.12.018_bib15","unstructured":"A study to evaluate tobevibart + elebsiran in chronic HDV infection [Available from: https:\/\/clinicaltrials.gov\/NCT06903338]."},{"key":"10.1016\/j.jhep.2025.12.018_bib16","unstructured":"A study to evaluate Tobevibart+Elebsiran in participants with chronic HDV infection not virologically suppressed with bulevirtide [Available from: https:\/\/clinicaltrials.gov\/NCT07128550]."},{"key":"10.1016\/j.jhep.2025.12.018_bib17","unstructured":"A study to evaluate Tobevibart+Elebsiran versus bulevirtide in chronic HDV infection [Available from: https:\/\/clinicaltrials.gov\/NCT07142811]."}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825027370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827825027370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:59:02Z","timestamp":1777528742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827825027370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0168827825027370"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.12.018","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tobevibart and elebsiran for the treatment of chronic hepatitis delta","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}